William T. Symonds

18.0k total citations · 3 hit papers
89 papers, 4.9k citations indexed

About

William T. Symonds is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, William T. Symonds has authored 89 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Hepatology, 49 papers in Epidemiology and 26 papers in Infectious Diseases. Recurrent topics in William T. Symonds's work include Hepatitis C virus research (57 papers), Liver Disease Diagnosis and Treatment (27 papers) and HIV/AIDS drug development and treatment (25 papers). William T. Symonds is often cited by papers focused on Hepatitis C virus research (57 papers), Liver Disease Diagnosis and Treatment (27 papers) and HIV/AIDS drug development and treatment (25 papers). William T. Symonds collaborates with scholars based in United States, Germany and France. William T. Symonds's co-authors include Robert H. Hyland, John G. McHutchison, Xiao Ding, Edward Gane, Evguenia S. Svarovskaia, M. Michelle Berrey, Eric Lawitz, R. Hindes, Diana M. Brainard and Catherine Stedman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

William T. Symonds

87 papers receiving 4.8k citations

Hit Papers

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3 2013 2026 2017 2021 2014 2013 2013 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
    2014 592 citations Stefan Zeuzem, Geoffrey Dusheiko et al. New England Journal of Medicine profile →
  2. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
    2013 542 citations Edward Gane, Catherine Stedman et al. New England Journal of Medicine profile →
  3. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    2013 438 citations Eric Lawitz, Fred Poordad et al. The Lancet profile →

Peers

William T. Symonds
Thomas Podsadecki United States
Fiona McPhee United States
Doris B. Strader United States
Kenneth Koury United States
Marc Bourlière France
Hadas Dvory‐Sobol United States
Fernando Lopes Gonçales Brazil
Edward Tam United States
Stefan Mauss Germany
Diana M. Brainard United States
Thomas Podsadecki United States
William T. Symonds
Citations per year, relative to William T. Symonds William T. Symonds (= 1×) peers Thomas Podsadecki

Countries citing papers authored by William T. Symonds

Since Specialization
Citations

This map shows the geographic impact of William T. Symonds's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William T. Symonds with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William T. Symonds more than expected).

Fields of papers citing papers by William T. Symonds

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William T. Symonds. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William T. Symonds. The network helps show where William T. Symonds may publish in the future.

Co-authorship network of co-authors of William T. Symonds

This figure shows the co-authorship network connecting the top 25 collaborators of William T. Symonds. A scholar is included among the top collaborators of William T. Symonds based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William T. Symonds. William T. Symonds is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kirby, Brian J., William T. Symonds, Brian P. Kearney, & Anita Mathias. (2015). Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clinical Pharmacokinetics. 54(7). 677–690. 196 indexed citations
2.
Rodríguez‐Torres, M., Anuj Gaggar, Gong Shen, et al.. (2015). Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1–4 in Patients Coinfected With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(5). 543–549. 23 indexed citations
3.
Charlton, Michael, Edward Gane, Michael P. Manns, et al.. (2014). Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology. 148(1). 108–117. 254 indexed citations
4.
Ruane, Peter, Richard Stryker, Peter Wolfe, et al.. (2014). Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. Journal of Hepatology. 62(5). 1040–1046. 122 indexed citations
5.
6.
Zeuzem, Stefan, Geoffrey Dusheiko, Riina Salupere, et al.. (2014). Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. New England Journal of Medicine. 370(21). 1993–2001. 592 indexed citations breakdown →
7.
Svarovskaia, Evguenia, Hadas Dvory‐Sobol, Viktoria Gontcharova, et al.. (2013). 1221 NO S282T MUTATION DETECTED BY DEEP SEQUENCING IN A LARGE NUMBER OF HCV PATIENTS WHO RECEIVED GS-7977 WITH RBV AND/OR GS-0938: THE QUANTUM STUDY. Journal of Hepatology. 58. S496–S496. 4 indexed citations
8.
Barrett, Lisa Feldman, Anu Osinusi, Anita Kohli, et al.. (2013). 1 ALTERED HCV SPECIFIC T CELL IMMUNITY VERY EARLY IN INTERFERON FREE HCV DAA THERAPY. Journal of Hepatology. 58. S1–S1. 13 indexed citations
9.
Lawitz, Eric, Fred Poordad, Phillip S. Pang, et al.. (2013). Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. The Lancet. 383(9916). 515–523. 438 indexed citations breakdown →
10.
11.
Gane, Edward, Catherine Stedman, Robert H. Hyland, et al.. (2013). Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection. Gastroenterology. 146(3). 736–743.e1. 157 indexed citations
12.
Gane, Edward, Catherine Stedman, Robert H. Hyland, et al.. (2013). Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C. New England Journal of Medicine. 368(1). 34–44. 542 indexed citations breakdown →
13.
Rodríguez‐Torres, M., Eric Lawitz, Kris V. Kowdley, et al.. (2012). Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. Journal of Hepatology. 58(4). 663–668. 85 indexed citations
14.
Dev, Anouk, William T. Symonds, Keyur Patel, et al.. (2008). Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. Journal of Viral Hepatitis. 15(8). 571–577. 11 indexed citations
15.
White, Ian R., Keyur Patel, William T. Symonds, et al.. (2007). Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. Journal of Translational Medicine. 5(1). 33–33. 43 indexed citations
16.
Symonds, William T., et al.. (2002). Risk factor analysis of hypersensitivity reactions to abacavir. Clinical Therapeutics. 24(4). 565–573. 90 indexed citations
17.
Polk, Ronald E., Michael A. Crouch, Debra S. Israel, et al.. (1999). Pharmacokinetic Interaction between Ketoconazole and Amprenavir after Single Doses in Healthy Men. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 19(12). 1378–1384. 35 indexed citations
18.
Drusano, George L., Brian M. Sadler, Judith Millard, et al.. (1997). Pharmacodynamics of 141W94 as determined by short term change in HIV RNA Influence of viral isolate baseline EC50. 37. 4. 4 indexed citations
19.
Nix, David E., et al.. (1997). Assessment of the Enzymuria Resulting from Gentamicin Alone and Combinations of Gentamicin with Various β-Lactam Antibiotics. Annals of Pharmacotherapy. 31(6). 696–703. 12 indexed citations
20.
Nix, David E., William T. Symonds, Judith M. Hyatt, et al.. (1997). Comparative Pharmacokinetics of Oral Ceftibuten, Cefixime, Cefaclor, and Cefuroxime Axetil in Healthy Volunteers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(1). 121–125. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Podsadecki Breakdown of academic impact, for papers by Fiona McPhee Breakdown of academic impact, for papers by Doris B. Strader Breakdown of academic impact, for papers by Kenneth Koury Breakdown of academic impact, for papers by Marc Bourlière Breakdown of academic impact, for papers by Hadas Dvory‐Sobol Breakdown of academic impact, for papers by Fernando Lopes Gonçales Breakdown of academic impact, for papers by Edward Tam Breakdown of academic impact, for papers by Stefan Mauss Breakdown of academic impact, for papers by Diana M. Brainard
Rankless by CCL
2026